Special Issue

Knowledge, Attitudes, Beliefs and Hesitancy towards COVID-19 Vaccination and Booster Doses

Message from the Guest Editors

COVID-19 was declared a pandemic by the WHO on March 11th, 2020, and since then, it has caused unprecedented morbidity and mortality worldwide. Apart from social distancing, hand hygiene, and mask wearing, the only effective way to curb this pandemic is through effective herd immunity, which can only be achieved through mass immunization of the general population. Even though the safety and effectiveness of COVID-19 vaccines are backed up by published scientific data, there is widespread hesitancy towards vaccination due to personal beliefs, religious practices, socioeconomic reasons, or political ideology. In this Special Issue, we aim to invite distinguished authors to publish manuscripts related to knowledge, attitudes, beliefs, and hesitancy toward COVID-19 vaccination. We also invite manuscripts on attitudes and beliefs towards COVID-19 vaccine booster doses in the general population and in special population groups such as cancer patients, immunocompromised patients, and transplant patients. We look forward to original research articles such as behavior surveys, systemic reviews, meta-analyses, review articles, or opinion pieces.

Guest Editors

Dr. Rahul Shekhar

University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA

Dr. Prabal Chourasia

Mary Washington Hospital, Fredericksburg, VA 22401, USA

Dr. Abu Baker Sheikh

Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87106, USA

Deadline for manuscript submissions

closed (31 May 2024)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/148197

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

